



<b>Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No. A31386-A (070165.0593)	Serial No. 09/855,886
	Applicant Coller et al. <b>ATTACH TO #12</b>	
	Filing Date May 15, 2001	Group Art Unit 1642
	Examiner Helms, L.	

**.U.S. PATENT DOCUMENTS**

*Exam. Init.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Appro.

**FOREIGN PATENT DOCUMENTS**

No.	Document No.	Date	Country	Class	Subclass	Translation Yes No

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)**

No.	
62.	Trikha et al., "Multiple Roles for Platelet GPIIb/IIIa and $\alpha_v\beta_3$ Integrins in Tumor Growth, Angiogenesis, and Metastasis," Cancer Res. 2002; 62:2824-2833.
63.	Trikha et al., "Platelets and Cancer: Implications for Antiangiogenic Therapy," Seminars in Thrombosis and Hemostasis 2002; 28:39-44.
64.	Cohen et al., "Potential Future Clinical Applications for the GPIIb/IIIa Antagonist, Abciximab in Thrombosis, Vascular and Oncological Indications," Pathol. Oncol. Res. 2000; 6(3):163-174.
65.	Coller, "Potential non-glycoprotein IIb/IIIa effects of abciximab," Am. Heart J. 1999; 138:S1-S5.
66.	Luna et al., "Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model." Lab. Invest. 1996; 75:563-573.

NY02:431027.1

Examiner

Date Considered

8/18/03